Literature DB >> 3790487

Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience.

P K Lommatzsch.   

Abstract

From 1964 to 1984 309 patients with choroidal melanoma were treated with 106Ru/106Rh beta ray applicators (1000 Gy at the apex of the tumour within 7-14 days). In cases 216 (69.9%) this treatment was successful for a mean follow-up period of 6.7 years after irradiation. In 53 cases (17.2%) the eye had to be enucleated, and 40 patients (12.9%) died from metastases within this period. Of the 216 successfully treated patients 114 (52.8%) developed flat scars and 49 (22.7%) retained a visual acuity of 1.5-0.5. Radiogenic late complications with damage to the retinal capillary system were the main causes of visual deterioration, especially in eyes with tumours close to the posterior pole. The survival rate is substantially higher than that for patients whose eyes were primarily enucleated. beta Ray applicators with 106Ru/106Rh can be recommended as an effective tool and a simple and cheap procedure to cure patients with small and medium sized choroidal melanomas. They save the eye without endangering our patients' lives.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790487      PMCID: PMC1040840          DOI: 10.1136/bjo.70.11.844

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Local radiotherapy in the treatment of malignant melanoma of the choroid.

Authors:  P A MacFaul
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09

2.  A moratorium on enucleation for choroidal melanoma?

Authors:  F A Jakobiec
Journal:  Am J Ophthalmol       Date:  1979-06       Impact factor: 5.258

3.  A crisis in the management of patients with choroidal melanoma.

Authors:  M Boniuk
Journal:  Am J Ophthalmol       Date:  1979-06       Impact factor: 5.258

Review 4.  Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators.

Authors:  P Lommatzsch
Journal:  Surv Ophthalmol       Date:  1974 Sep-Oct       Impact factor: 6.048

5.  [Radiotherapy of intraocular tumours, particularly of melanoma of the choroid (author's transl)].

Authors:  P K Lommatzsch
Journal:  Klin Monbl Augenheilkd       Date:  1979-06       Impact factor: 0.700

6.  Radiotherapy for malignant melanoma of the choroid.

Authors:  H B Stallard
Journal:  Br J Ophthalmol       Date:  1966-03       Impact factor: 4.638

7.  beta-Ray treatment of malignant epibulbar melanoma.

Authors:  P K Lommatzsch
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-12-15

8.  [Survival after treatment for malignant choroidal melanoma: comparison between conservative therapy (Ru106/Rh106 applicator) and enucleation with and without postoperative irradiation to the orbit; 1960 to 1979].

Authors:  H Kiehl; I Kirsch; P Lommatzsch
Journal:  Klin Monbl Augenheilkd       Date:  1984-01       Impact factor: 0.700

Review 9.  Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.

Authors:  L E Zimmerman; I W McLean; W D Foster
Journal:  Br J Ophthalmol       Date:  1978-06       Impact factor: 4.638

10.  Radiation therapy of choroidal melanoma.

Authors:  M Rotman; R S Long; S Packer; H Moroson; M A Galin; B Chan
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09
View more
  34 in total

1.  Indirect ophthalmoscope laser treatment as supplement to 125I plaque therapy for choroidal melanoma.

Authors:  J J Augsburger; D Mullen; M Kleineidam
Journal:  Trans Am Ophthalmol Soc       Date:  1992

2.  Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

3.  Cobalt plaque radiotherapy versus enucleation for posterior uveal melanoma: comparison of survival by prognostic index groups.

Authors:  J J Augsburger; J W Gamel; J A Shields
Journal:  Trans Am Ophthalmol Soc       Date:  1989

Review 4.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

5.  Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

Authors:  D H Char; S Kroll; J M Quivey; J Castro
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

7.  Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.

Authors:  Alexander Böker; Daniel Pilger; Dino Cordini; Ira Seibel; Aline I Riechardt; Antonia M Joussen; Nikolaos E Bechrakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-16       Impact factor: 3.117

8.  Histopathology studies in human malignant melanomas of the choroid after unsuccessful treatment with 106Ru/106Rh ophthalmic applicators.

Authors:  H Klaus; P K Lommatzsch; U Fuchs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

9.  Phototherapy of posterior uveal melanomas.

Authors:  I Favilla; W R Barry; A Gosbell; P Ellims; F Burgess
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

10.  Treatment of juxtapapillary melanomas.

Authors:  P K Lommatzsch; R Lommatzsch
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.